Skip to main content
    L

    Legend Biotech Corp (LEGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.99
    -1.51 (-8.63%)

    Market Cap: $3.39B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Legend Biotech Corp (LEGN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Legend Biotech (LEGN) to earn -$0.01 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.43B. Of 13 analysts, 8 rate the stock Buy or Strong Buy, 5 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.64.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 62% of the ratings.

    RatingAnalystsShare
    Strong Buy538.5%
    Buy323.1%
    Hold538.5%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 18.9%.

    Fiscal year ending Dec 31, 2026
    -$0.01
    EPS consensus, revenue $1.43B
    Fiscal year ending Dec 31, 2027
    $0.64
    EPS consensus, revenue $1.70B
    Fiscal year ending Dec 31, 2028
    $1.34
    EPS consensus, revenue $2.06B
    Next report
    Mar 8, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.01-$0.01 to -$0.011$1.43B$1.42B to $1.44B7
    Dec 31, 2027$0.64$0.32 to $1.056$1.70B$1.61B to $1.84B10
    Dec 31, 2028$1.34$1.02 to $1.662$2.06B$2.01B to $2.11B10

    Quarterly Estimates

    The EPS consensus rises from $0.04 for the quarter ending Dec 31, 2026 to $0.13 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.04-$0.02 to $0.1314$389.25M$360.64M to $414.48M12
    Mar 31, 2027$0.13$0.13 to $0.131$401.90M$380.00M to $443.19M3

    Estimate Revisions

    No EPS estimate for the 3 periods below was revised in the last 30 days.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202700
    Quarter ending Mar 31, 202700

    EPS Trend

    The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.01-$0.01-$0.01-$0.01-$0.01N/A
    Fiscal year ending Dec 31, 2027$0.64$0.68$0.68$0.81$0.88-28.1%
    Quarter ending Mar 31, 2027$0.13$0.13$0.13$0.13$0.22-40.9%

    Frequently Asked Questions About LEGN

    What is the LEGN stock forecast?

    Consensus analyst estimates put Legend Biotech's EPS at -$0.01 for the fiscal year ending Dec 31, 2026, on revenue of $1.43B. The consensus rating from 13 analysts is Buy.

    How do analysts rate LEGN stock?

    Of 13 analysts covering Legend Biotech, 5 rate it Strong Buy, 3 Buy, 5 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from LEGN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.01, with estimates from -$0.01 to -$0.01 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.64, with estimates from $0.32 to $1.05 from 6 analysts.

    What revenue do analysts expect from Legend Biotech next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.43B, with estimates from $1.42B to $1.44B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.70B, with estimates from $1.61B to $1.84B.

    How many analysts cover LEGN?

    13 analysts rate Legend Biotech stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.